| # | Drug | Count |
|---|---|---|
| 0 | TRASTUZUMAB | 5 |
| 1 | VANDETANIB | 5 |
| 2 | BEVACIZUMAB | 4 |
| 3 | OXALIPLATIN | 4 |
| 4 | REGORAFENIB | 4 |
| 5 | VISCUM ALBUM FRUITING TOP | 4 |
| 6 | ALBUTEROL SULFATE | 2 |
| 7 | CAPECITABINE | 2 |
| 8 | ERGOCALCIFEROL | 2 |
| 9 | FILGRASTIM | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | VANDETANIB | 5 | 0.0028 |
| 1 | ROLAPITANT | 1 | 0.0019 |
| 2 | DHEA (DEHYDROEPIANDROSTERONE) | 1 | 0.0005 |
| 3 | CAPMATINIB | 1 | 0.0004 |
| 4 | REGORAFENIB | 4 | 0.0003 |
| 5 | BEVACIZUMAB-AWWB | 1 | 0.0002 |
| 6 | AFATINIB | 1 | 0.0002 |
| 7 | ELACESTRANT | 1 | 0.0001 |
| 8 | CIMETIDINE | 1 | 0.0001 |
| 9 | ENCORAFENIB | 1 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Provitamin D2 Compound [EPC] | 2 | 0.0001 |
| 1 | HER2/neu Receptor Antagonist [EPC] | 5 | 0.0001 |
| 2 | Thrombopoietin Receptor Agonist [EPC] | 1 | 0.0001 |
| 3 | Non-narcotic Antitussive [EPC] | 1 | 0.0001 |
| 4 | Estrogen Receptor Antagonist [EPC] | 2 | 0.0000 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 4 | 0.0000 |
| 6 | Nucleoside Analog Antiviral [EPC] | 2 | 0.0000 |
| 7 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 4 | 0.0000 |
| 8 | Epidermal Growth Factor Receptor Antagonist [EPC] | 1 | 0.0000 |
| 9 | CTLA-4-directed Blocking Antibody [EPC] | 1 | 0.0000 |